Figure 2.

Clinical and immunological responses to cycle 1 rituximab therapy in pSS. Clinical measures before and 6 months after rituximab were assessed using (A) the ESSDAI, (B) clinical ESSDAI (without biological domains), and (C) oral prednisolone dose. (D) The number of patients with various degree of responses or a new flare at 6 months in the 11 main ESSDAI domains. (E) IgG levels (g/L) were compared before and after rituximab. Bar chart in A‐C and E denote mean and error bars show standard error of the mean. Paired student t test were used for comparison. CRP, C‐Reactive Protein; ESSDAI, EULAR Sjögren syndrome disease activity index; pSS, primary Sjögren syndrome; RTX, rituximab.